Antibodies News and Research

RSS

Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2

In a new study published on the preprint server bioRxiv researchers characterized the crystal structure of the antibody-SARS-CoV-2 RBD complex in an attempt to find the epitope and the mechanism that enables cross-neutralization.

5 Aug 2020

Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy

Yellow fever, an acute viral hemorrhagic disease transmitted by infected mosquitoes, infects about 200,000 people and causes an estimated 30,000 deaths each year.

5 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

De novo protein decoys that block SARS-CoV-2

Now, a new study published on the preprint server bioRxiv in August 2020 shows that computational design technology can be efficiently harnessed towards this end, producing new molecules to inhibit viral entry and replication.

5 Aug 2020

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG.

4 Aug 2020

NIH trial to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

4 Aug 2020

Decoy receptor neutralizes SARS-CoV-2 virus in tissue cultures

As the COVID-19 pandemic continues to spread, scientists and health care providers are seeking ways to keep the coronavirus from infecting tissues once they're exposed. A new study suggests luring the virus with a decoy - an engineered, free-floating receptor protein - binds the virus and blocks infection.

4 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Yale researchers develop new mouse model to study SARS-CoV-2 infection

Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus.

4 Aug 2020

Five alternative methods of SARS-CoV-2 suppression

The current pandemic has proved to be challenging to control without stringent and comprehensive non-pharmacological interventions (NPIs), relying mostly on isolation and contact tracing of cases, along with social distancing. However, strategies like these have a huge human cost in terms of restriction of social interactions, resulting in depressive tendencies, disruption of economic activity, and loss of educational resources.

3 Aug 2020

A new platform to provide information on SARS-CoV-2 immunity or seroprevalence

Who has overcome an infection with the virus without noticing, and how many people have already produced protective antibodies against the new coronavirus? Various antibody studies are now under way that will provide information on immunity or seroprevalence in the population.

3 Aug 2020

Study shows high SARS-CoV-2 seroprevalence, but low death rate in Malawi's health care workers

A study by researchers from Malawi and United Kingdom reveals a significant discrepancy between predicted coronavirus disease (COVID-19) mortality in the observed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence rates in health care workers and reported deaths in urban Malawi in southeastern Africa, indicating early exposure, but a slow progression of the outbreak. Their findings are currently available on the medRxiv preprint server.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Maternal vaccination could protect infants against RSV illness

Immunizing pregnant women with a potential vaccine against RSV could prevent the most common cause of pneumonia in their babies.

3 Aug 2020

New method to detect rare circulating tumor cells in blood samples

Metastasis - the development of tumor growth at a secondary site - is responsible for the majority of cancer-related deaths. It occurs when the primary tumor site sheds cancerous cells which are then circulated through the body via blood vessels or lymph nodes.

3 Aug 2020

Immune system's oldest branches may underpin COVID severity

One of the immune system's oldest branches, called complement, may be influencing the severity of COVID disease, according to a new study from researchers at Columbia University Irving Medical Center.

3 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

The race to a coronavirus vaccine

As the number of coronavirus disease (COVID-19) cases skyrocket to a staggering 18 million, the race to attain vaccine approval is on. More than a hundred candidate vaccines are being developed and tested to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, many vaccine candidates are undergoing human stage 2 and 3 trials to prove their efficacy and safety.

2 Aug 2020